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Abstract
Background: Hepatitis C virus reinfections in HIV-positive men-who-have-sex-with-men (MSM) challenge the
effectiveness of antiviral treatment. To fight this problem, an adapted sexual risk reduction intervention was
implemented within a hepatitis C treatment trial. Following this, the current study had two aims and describes 1)
how the program was received by participants; and 2) their responses to the program regarding sexual risk taking.
Based on the participants’ input, we hoped to judge the intervention’s potential for scale-up.
Methods: Seventeen participants who received the sexual risk reduction intervention in addition to hepatitis C
treatment were recruited for semi-structured interviews six to 12 months post-intervention. We evaluated the
responses via reflexive thematic analysis and applied the concept of sense-making.
Results: Giving hepatitis C a place and living without it again illustrates how participants received the program and
how their experiences were altered by the impact of sense-making. Based on their responses, we allocated
participants to three groups: 1. Avoid risks: get rid of hepatitis C for life. For these men, hepatitis C remained a life-
threatening disease: they actively modified their risk behavior and felt supported by the intervention in maintaining
their behavioral changes. 2. Minimize risks: live as long as possible without hepatitis C. In contrast to group 1, these
men saw hepatitis C as a manageable disease. The intervention facilitated reflection on risks and how to develop
behavioral changes that suited them individually. 3. Accept risks; live with the risk of hepatitis C. These men perceived
behavioral changes as much more difficult than “easy” medical treatment. They expected to either undergo
repeated rounds of treatment or stay HCV re-infected.
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Conclusion: These results illustrate the diversity of men’s responses and their decisions regarding sexual risk
behavior after participating in a combination of antiviral treatment and a sexual risk reduction intervention. Two
major aspects were identified: 1) Teachable moments, particularly at the time of diagnosis/treatment, could offer an
opportunity to develop openness for behavioral change; 2) adapting sexual risk reduction interventions to sense-
making patterns could help to improve its effectiveness. Support for reducing infection risk and raising awareness
of preventative measures are additional benefits.
Trial registration: Clinical Trial Number: NCT02785666, 30.05.2016.
Keywords: Hepatitis C, HIV, MSM, Sense-making, Health behavior, Qualitative
Background
Since 2014, chronic hepatitis C virus (HCV) infection
has been easily curable with direct acting antivirals
(DAAs), leading to enhanced survival, reduced liver-
related morbidity, improved quality of life, and preven-
tion of extrahepatic complications [1–5]. Accordingly, in
2016 the World Health Organization (WHO) set targets
to eliminate HCV as a public health threat by 2030.
Alongside an 80% reduction of infections, these included
increasing diagnoses and treatment by 90 and 80% re-
spectively [6].
In order to reach these targets, one key population for
multiple HCV prevention strategies was identified: men
who have sex with men (MSM) and who are living with
HIV. Members of this group have a high anti-HCV
prevalence (3–39%); and, as early as 2007, their inci-
dence of infection was increasing by 2.34–5.11 per 100
person-years (py) [7]. Within the Swiss HIV Cohort
Study (SHCS), MSM showed an 18-fold increase in
HCV infections between 1998 and 2011, peaking at a
rate of approximately 20 new infections per 100 py [3].
Importantly, since the introduction of direct-acting anti-
virals, many HIV-positive MSM have undergone suc-
cessful treatment, i.e., have shown a sustained viral
response after 12 weeks after the end of treatment
(SVR12), and then became re-infected in a median of
100–500 days [8, 9].
To reduce HCV incidence, including reinfections, ex-
perts recommend not only scaling up HCV treatment,
but also implementing interventions for risk reduction
[10]. Therefore, we launched the Swiss HCVree Trial to
test a micro-elimination strategy in this population.
Micro-elimination involves precise targeting of a single
sub-group’s needs [11]. In this trial, HIV-positive MSM
participating in the SHCS [12] were systematically
screened for HCV RNA. Positively diagnosed partici-
pants were offered treatment; those who accepted were
invited to participate in a sexual risk reduction interven-
tion [13].
Preparing the Swiss HCVree Trial’s, interventions for
sexual risk reduction targeting MSM focused predomin-
antly on reducing the risk of contracting or transmitting
HIV via condom use. However, in the members of this
subgroup of HIV-positive MSM, who are especially at
risk for HCV reinfection, targeting sexual risk behavior
linked closely to HCV transmission would require new
and expanded approaches. Specifically, sexual practices
leading to mucosal trauma, e.g., chemically prolonged
receptive intercourse, receptive fisting, receptive use of
sex toys, anal douching, group sex and the sharing of
snorting drugs in such contexts, are strongly associated
with HCV infection [14–19]. Also, increases in sex-
related recreational drug use, e.g., sharing of syringes, or
practices that increase the potential for anal or rectal
trauma due to longer and more intense sexual encoun-
ters, often with multiple partners, has made MSM the
highest-risk group for HCV infection [14, 20–23]. Over
recent decades, HIV-positive MSM have increasingly en-
gaged in condomless sexual contact with other HIV-
positive MSM, leading to a higher likelihood of HCV
transmission [24]. And since 2008, the concept of U=U
(HIV undetectable = untransmissible) has led to ongoing
decreases in condom use [25, 26]. To cover the full
range of these changes, we adapted an evidence-based
counseling intervention to improve self-regulation of
risks associated with specific sexual behaviors and sexu-
alized drug use. We implemented this intervention in
parallel with HCV treatment [27].
Specific barriers to evaluating an intervention for sex-
ual risk reduction were relevant to our study setting.
First, the Swiss HCVree Trial ran in a real-world context
with the goal of micro-elimination of HCV within the
population of MSM with HIV/HCV co-infection. This
rendered a controlled trial design impossible. Second,
considering that, at the time (2016), no HCV specific
intervention had been developed for this population, we
systematically adapted our intervention from an HIV
sexual risk reduction program [28]. This adaptation was
informed by a group of four MSMs co-infected with
HIV/HCV. Because of time constraints, we were unable
to include a broader community in the co-creation
process as described by Prinsenberg et al. [29]. Given
these two limitations, we prioritized evaluating our inter-
vention qualitatively after participants received the
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intervention. Our aims were to describe participants’ ex-
periences with the program and to answer questions 1)
about how the program was received by participants;
and 2) their responses to the program regarding sexual
risk taking. Based on participants’ input, we intended to
further develop the intervention and its inherent poten-
tial for scale-up activities on this and similar initiatives.
Method
With a constructivist orientation, we followed Braun and
Clarke’s reflexive thematic analysis approach [30, 31].
Our interest was to understand the responses of MSM
to this comprehensive prevention strategy, their experi-
ences using an intervention for sexual risk reduction
combined with DAAs treatment.
To aid our interpretation, we employed the concept of
sense-making. Triggered by new situations, sense-
making is the process of perceiving patterns within com-
plex social environments and phenomena. These pat-
terns can then be used to react to similar situations [32,
33]. Understanding the sense-making strategies of our
participants will help us not only to understand the vari-
ous participant responses to the intervention, [34] but
also to identify themes, commonalities and differences
between their sense-making processes [35].
Setting and sampling
This study was embedded in the Swiss HCVree Trial [13,
36]. Between 2016 and 2017, 122 HIV/HCV co-infected
MSM, all participants in the SHCS, accepted the offer of
free DAAs treatment in one of Switzerland’s seven spe-
cialized HIV outpatient clinics. The study was conducted
irrespective of DAAs restrictions existing at the time
(high medication costs had led to treatment being re-
served for only patients with advanced liver fibrosis or
cirrhosis) [11, 37]. All MSM who reported inconsistent
condom use for anal intercourse with non-steady part-
ners during the previous year (n = 72) were invited to
participate in the behavioral intervention [38]. At that
time, this was the best-known risk behavior for HCV ac-
quisition among SHCS participants and allowed us to
more easily estimate the number of potential partici-
pants who could be included in the behavioral interven-
tion (to allow provision of adequate resources). Fifty-one
agreed to take part. As all had received both DAAs treat-
ment and the behavioral intervention, all were eligible
for this qualitative study.
We used a purposive sampling approach, which
allowed us to include a diverse range of participants
[39]. The final sample included MSM a) of various ages;
b) across a broad range of years since their HCV and/or
HIV diagnosis; c) with various numbers of HCV treat-
ments (especially former Interferon-based treatment); d)
receiving treatment at various clinics; and e) with
various levels of experience with counselors. Potential
participants were recruited by their responsible clini-
cians. Of 51 intervention participants, 21 were invited to
participate in the interviews, of whom 17 agreed and
provided written informed consent. In all cases of non-
participation, the reason given was lack of time.
The behavioral intervention
HCVree and me is a theory-based intervention using an
adapted version of the information-motivation-behavioral
(IMB) skills model [40, 41], social cognitive theory (SCT)
[42] and theoretical aspects of cognitive neuroscience.
The intervention consisted of four individual eHealth-
assisted counseling sessions, which were scheduled for
treatment weeks 4, 6, 8 and 12. The sessions were carried
out by nurses trained in motivational interviewing tech-
niques and the eHealth program.
The first session focused on exploring the emotions
and values of participants regarding sexual behavior.
This process was guided by video clips of actors portray-
ing scenarios described by patients living with HIV/
HCV. These clips were intended to evoke emotions,
highlight implicit thought processes and encourage self-
reflection regarding sexual risk-taking. A selection of
thirteen video clips was available, from which the par-
ticipant could choose up to three that were related to
their personal experiences. We used these clips to both
engage participants emotionally in relation to their own
practices and attitudes, and present potential role
models to support active learning. The second counsel-
ing session focused on perceived benefits and disadvan-
tages of the participant’s sexual conduct. This was again
supported by the video clips and interactive information
(e.g., ‘What do we know about HCV risk factors?’ or
‘What does safe substance use mean?’). The third session
focused on setting individual goals for behavior change.
In the fourth and final session, these goals were revisited
to re-assess and adapt the initial change processes.
Data collection
Data were collected via semi-structured individual inter-
views 6–12 months post-intervention (end of treatment
and behavioral intervention). The interviewers followed
an interview guideline with open-ended questions about
participants’ experiences with and perceptions of the
intervention (e.g., ‘If you think back, what do you remem-
ber of the behavioral program and why?’). We prompted
participants to first describe notable situations that they
experienced during the intervention, and later to reflect
on any thoughts, emotions and behaviors that they per-
ceived in relation to the program. Based on their re-
sponses, the interviewer then delved into topics such as
their experience of living with HCV and/or HIV, HCV
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treatment, their HCV cure, and their former or current
sexual risk behaviors.
Four female researchers (PKH, KF, MR, DN) con-
ducted the individual interviews. All were academically
trained nurses with experience in both qualitative data
collection and developing interventions. All four re-
searchers were also counselors in the Swiss HCVree
Trial. Participant reflections on the intervention were
able to be elicited in detail—as opposed to simple de-
scriptions— largely due to the interviewers’ in-depth
knowledge of the intervention [35]. However, to support
the openness and critical feedback from participants, it
was important that the interviewers had no former rela-
tionship with any of the interviewees (including as
counselors).
Initial data analysis was conducted after the first three
interviews, after which new questions were added based
on the results from this analysis. Individual interviews
lasted 37–77min (mean: 48). According to participant
preferences, eleven interviews took place at the out-
patient clinic and six at their residence. All interviews
were audio-recorded and transcribed verbatim.
Data analysis
We followed Braun and Clarke’s six-phase reflexive the-
matic analysis approach [30, 31]. Our main analytical
goal was to identify patterns of meaning across the data
set that could clarify how participants responded to the
program.
Analysis began with data familiarization (phase 1).
Two researchers (PKH/DN) carefully read each tran-
script, discussed their initial notes, and then summarized
their discussion in visual maps with preliminary concep-
tual definitions. In Phase 2, the first author began sys-
temically identifying meaning throughout the dataset,
conferring regularly with the co-authors. Similar mean-
ings were collated into different codes. These codes
helped to organize the data. Then, we developed themes
based on codes, analytical memos and input from our
discussions (Phase 3). Later, themes were continuously
developed into meaning patterns (Phase 4). Via system-
atic review and comparison with our source data, we
confirmed emerging meaning patterns and further iden-
tified subtle but important differences between partici-
pants (e.g., some men spoke about behavior changes
before counseling started, others did not; perceptions
varied regarding the severity of HCV infection). To ac-
count for such variation, we constructed groups illustrat-
ing the diversity of sense-making work in relation to the
program. In Phase 5, we discussed the meaning patterns
extensively within the research group. Taking place at
institutional research meetings, these discussions in-
volved one patient representative who was not a study
participant. The resulting feedback led to refinement of
the meaning patterns. Finally, during Phase 6, two re-
searchers (PKH/DN) produced the study report. For
transcript analysis, we used the MAXQDA Plus 2018
software (version 18.2.0).
Results
Seventeen participants reported both on their experi-
ences within the program and on their ongoing re-
sponses. All had achieved a sustained viral response
(SVR12) with DAAs. They had a median age of 44 years
(interquartile range (IQR): 41–53). They had known of
their HIV infection for a median of 10.9 years (IQR 6.5–
17.3) and of their HCV infection for a median of 1.6
years (IQR 1.2–4.1). Six had had experience with the
earlier Interferon-based therapy prior to DAAs treat-
ment. Two whose HCV infections were cleared by this
therapy were participating in the Swiss HCVree Trial, re-
ceiving DAAs treatment for HCV reinfection, Table 1.
Interviewee responses to the intervention program
were influenced by their various life situations, and expe-
riences with chronic HCV infection and its treatment,
especially the current DAAs treatment within the Swiss
HCVree Trial, influenced their responses to the inter-
vention program. Accordingly, we identified the main
theme of Giving hepatitis C a place and living without it
again which describes how participants received the pro-
gram and how their experiences were altered by the im-
pact of sense-making. This is followed by descriptions of
three explanatory subthemes, each of which accounts for
a major participant group: 1) Avoid risks: get rid of hepa-
titis C for life; 2) Minimize risks: live as long as possible
Table 1 Participant characteristics
Variable Participants (n = 17)
Median age (interquartile range (IQR)) 44 (41–53)
White skin color, n (%) 16 (94)
Post-secondary education, n (%) 8 (47)
Number of participants living in steady
partnerships, n (%)
9 (53)
Median years since HIV diagnosis (IQR) 10.9 (6.5–17.3)
Median years since HCV diagnosis (IQR) 1.6 (1.2–4.1)





Former HCV treatment experience, n (%)
Naïve 10 (59)
With Interferon 6 (35)
With DAAs 1 (6)
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without hepatitis C; and 3) Accept risks: live with the risk
of hepatitis C (see Fig. 1).
Giving hepatitis C a place and living without it again
Giving hepatitis C a place describes how the participants
approached the behavioral intervention. This was in-
fluenced by their understanding of how chronic in-
fection would affect their lives. In addition to their
experience of DAAs therapy during the study, the
behavioral intervention altered their perceptions. Liv-
ing without it again describes how participants envi-
sioned the perceived impact of the behavioral
intervention and how they felt —especially with re-
spect to estimating the risk of possible reinfection—
after being cured.
For all interviewed men, their hepatitis C diagnosis
was unexpected. They reported trying to understand
not only how they became infected, but also how they
could evaluate the disease’s severity and its meaning
for their lives. How they dealt with this phase influ-
enced their later strategies to reduce the risk of pos-
sible reinfection. While some developed explanations
that they considered valid, others reported lasting un-
certainty, especially regarding transmission. One man
said:
So for me, there were three relatively surprising
[HCV] infections. And so therefore maybe I had
more of a need than others to explore where those
could have come from. Sure, there is always the risk
component. But in my mind, I don’t find that part
of it so large. And that’s why it’s not understandable
to me. (P9, 52 years (yrs))
Later, the participants reported that, when they agreed
to the behavioral intervention, they did not expect to
personally benefit from it. Some had explicitly asked if
they could potentially discontinue the study if they did
not feel that the intervention addressed them directly
(discontinuation was, of course, possible for all). How-
ever, all participants reported positive experiences in
that they felt being directly and personally addressed by
both the nurse counselor and the content of the pro-
gram. Several participants were surprised that they could
reflect seriously on themes that were relevant to them in
ways that helped them to better understand their own
infections and behavior. One participant expressed this
experience as follows:
In many discussions, it was really about me. It was
about understanding myself! And what I really want
to do. [...] No one said, you should do this or that—-
not at all! And that was something new. (P6, 42 yrs)
While the intervention sessions were positive, the ex-
perience of being cured of hepatitis C was also tremen-
dously important. However, this was not necessarily
interpreted in a positive way: Some reported that being
cured evoked a feeling of personal vulnerability from be-
ing newly infected with HCV, which they had to learn to
cope with. As one man explained,
I have to deal with this whole crap again. Now, one
has to be careful again. So a lot of stuff came up
again. A lot of dark stuff and fears. And yeah, al-
most a little of the feeling that I don’t go through
this again. (P16, 54 yrs)
Fig. 1 Overview of our main theme and the three subgroups to summarize the diversity of participants’ sense-making
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While the main theme (Giving hepatitis C a place and
living without it again) was central for all participants,
the following paragraphs describe how the three ex-
planatory models reflect the wide range of belief systems
and sense-making, all of which were influenced by the
contextual realities of participants.
Avoid risks: get rid of hepatitis C for life
Avoid risks: get rid of hepatitis C for life refers to a
sense-making work shared by men who saw hepatitis C
as serious and who took active steps to modify their risk
behavior—even before beginning treatment and counsel-
ing in most cases. These individuals had already initiated
lifestyle changes, which were felt to be supported by the
intervention, and aimed to avoid risks and stay free of
hepatitis C for the rest of their lives.
Men who used this sense-making work found them-
selves confronted with an illness that they had not even
considered before their diagnosis. They reported consid-
ering HCV infection something alien—a virus relevant
for intravenous drug users, not for them. The diagnosis
forced them to think about hepatitis C seriously, to iden-
tify risk situations where they had been exposed, and to
explain the reason for their infection. One man recalled
a situation as one
where in the past you went wild with drugs, in the
scene, drugs and party culture. Where night after
night you took Ecstasy and went wild dancing. And
then of course you had a relatively large number of
sex partners, which changed up a lot. That was be-
fore [my current] relationship. (P11, 52 yrs)
They assigned these risk situations to time periods char-
acterized by carelessness and eagerness to experiment
sexually. Three gave particularly noteworthy reports of
their lifestyle adjustments—of how they had to cut their
risks partly because of their hepatitis C diagnoses and
partly because they had formed lasting partnerships. As
all but a few had received their diagnoses before any reli-
able therapy (DAAs) became available (median time
since diagnosis: 5.8 years) most had tried to come to
terms with the thought that they carried a serious com-
municable chronic condition.
For many, from the moment they were diagnosed,
hepatitis C was always on their mind. One recognized it
as a “serious and socially limiting problem.” For example,
“HepC gobbles up energy,” leads to liver damage, and
poses a huge problem for any sexual partner because of
the danger of transmission.
These men embraced the possibility of being cured as
wonderful. They viewed DAAs as “a stroke of luck,” “an
immense chance.” A 45-year-old man said “the therapy
has given me a new life.” Even after study screening and
before treatment started, this group’s appreciation ap-
peared to motivate them toward intervention-independent
behavioral changes. Two men had already tried to practice
sex with multiple partners only with condoms or to stop
sexualized drug use because they had observed themselves
becoming more reckless in recent years. Two others said
they had stopped all sexual contact when their participa-
tion in the trial began.
Upon entering the intervention, based on their early
reflections about the disease, transmission routes of
hepatitis C and their behavioral changes, their attitude
was: “If it doesn’t help, it at least won’t make things
worse.” After all, they already had considerable know-
ledge and did not expect any personal gains. Many re-
lated how they had been positively surprised by the
intervention, perceiving it as an environment in which
they felt personally cared for and understood regarding
the challenge of changing their sexual risk behavior.
How one individual described it:
[The counseling] was very informative and what did
it bring? You also thought about yourself again a
little. That had maybe gotten a little lost lately. And
it was also nice somehow to know that there are
people who are at all interested. And that is for me
also a nice aspect of the story. (P8, 28 yrs)
At the time of the intervention, the participants gener-
ally felt they were already moving in the right direction,
but wanted to achieve and maintain “the strict practice
of safer sex.” In the long run, they saw absolute avoid-
ance of risk as the only way to maintain their health.
This is why they used the intervention to discuss situa-
tions that were awkward and difficult for them: they
wanted to be better prepared.
They also appreciated that during the intervention, ac-
cording to their own personal interests, they could de-
cide on the direction of their discussions. Among the
intervention’s other benefits, they appreciated the oppor-
tunity it offered to reflect on their “previous high-risk sex
life”—the lifestyle that had led them to acquire the
disease. They recognized during the interview that their
experiences with risks were something useful, an import-
ant resource in the current situation:
The light went on for me. In the sense of just think-
ing before you do something. Before, I didn’t have
any knowledge of where you can get hepatitis C.
You simply go too far and now you say to yourself:
I won’t let it go so far again. (P12, 39 yrs)
A general consensus among members of this participant
group was that, combined with the behavioral interven-
tion, their successful treatment had reinforced their
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intention to build on and maintain the lifestyle changes.
For them, using condoms for anal intercourse, while
avoiding both mucosal trauma and drugs, made sense.
They saw the cure of their hepatitis C as a unique
chance and decided to avoid any contact with the virus
in the future. Feeling relieved and happy, they experi-
enced the cure as liberating.
One described it as “a success that [he] was permitted
to experience thanks to the therapy.” They considered a
reinfection as a personal failure, as a disgrace not only to
themselves but to their doctors. One man described how
the risk of reinfection was a source of fear that led to
increased caution after cure:
It was strange in the beginning after the treatment.
I was overly careful. I wasn’t even able to enjoy it,
because I was afraid. That it turned out so well and
that I don’t have it anymore. That was always a
topic. (P4, 45 yrs)
Men in this group believed that their only hope for stay-
ing free of HCV was to avoid risks. Therefore, they had
resolved not to expose themselves further. Their shared
goal was never to be infected with hepatitis C again—to
get rid of hepatitis C for life.
Minimize risks: live as long as possible without hepatitis C
This theme showed a sense-making process prevalent in
men who considered hepatitis C a problematic but man-
ageable disease. They described the behavioral interven-
tion as helpful to facilitate thinking about risks and how
to develop behavioral changes suitable for their long-
term aim of living well without hepatitis C.
Compared with the first group, these men had only re-
cently become aware of hepatitis C (median time since
diagnosis: 1.6 years), with diagnoses received, in most
cases, during regular STI testing. Unlike the earlier
group, before their diagnoses, they had had vague know-
ledge of hepatitis C, but had paid little attention to it
until they tested positive. The diagnosis had typically
come as a surprise because, compared to their peers,
they did not consider to be at high risk. Their diagnoses
had made them uncertain of how to gauge the relative
risks of various behaviors. They concluded that they
must have contracted the virus in an exceptional situ-
ation. They further said that they had practiced condom-
less anal sex with multiple (HIV-positive) partners for
years. Since the hepatitis C diagnosis was made after
such a long time, they concluded that this behavior
couldn’t be particularly risky and were uncertain about
how to protect themselves and others:
[I regularly participated in sexual practices] without
a condom. I did it like this for a long time before
that, and hepatitis C didn’t happen until 2015. I
surely didn’t use … [condoms] for ten years. And I
had unprotected sex just as often during these ten
years. (P13, 54 yrs)
Like the earlier group, these men were concerned about
infecting their sex partners. However, they adhered to
their original explanatory model—that they had
contracted HCV during a single exceptional situatio-
n—and did not report any changes in their behavior
prior to the start of the intervention program.
Similar to the first group, these men were pleased to
take part in the study, and to receive the highly-effective
and expensive medication free of charge. They said that
when they learned of the new DAAs treatment, which
was both simpler and more effective than its Interferon-
based version, they concluded that “hepatitis C can
cause issues that are to some extent manageable.”
Unlike the earlier group, these men agreed to the
intervention mainly because they saw it as a possibility
“to return something because [they were] receiving DAAs
with voluntary participation.” Some also hoped to learn
more about hepatitis C:
The knowledge, that’s what I was looking for. The
knowledge about this, also in our community, is not
really succinct or firmly understood. And for that
reason, the probability of taking risks is much
higher. (P3, 57 yrs)
All participants had enjoyed the behavioral intervention.
In addition to the medical treatment, they appreciated
the possibility of talking to a highly-knowledgeable nurse
counselor who did not judge them. For this group, the
knowledge gained during the intervention was a sudden
insight. They were impressed by the fact that various sit-
uations could result in infection — for example, use of
anal douching equipment (the act of flushing out one’s
rectum with water or other liquids) or even of straws for
intranasal drug consumption. From the information they
received, they concluded that one of the intervention’s
main messages was that “HepC is easy to get and can
also return.” One even described the virus as particularly
“malicious.”
Another difference between this group and the first
was that the behavioral intervention motivated them to
reflect on their own sexual preferences and the associ-
ated risks. During discussions with the counselor, they
reflected on their personal risk situations and openly dis-
cussed possible changes to their behavior.
With their counselling sessions, they were supported
in their choices for or against certain changes which
could be considered by them easier to make—a dynamic
reflected clearly in their perception of practicability. For
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example, these men did not see regular condom use as
feasible, because they did not feel ready for it. Instead,
members from this group chose changes they considered
easily made, such as “using gloves when fisting in a safe
way “or “not sharing sex toys with other people.”
Regarding behavioral changes, this group’s members
also had less strict ideas than the first, adhering instead
to the strategy of “trying and choosing behavioral
changes suitable for myself.” They felt that the interven-
tion supported them in maintaining feasibly judged be-
havioral changes. Some said they participated less often
in sex parties, opting instead to organize non-sexual leis-
ure weekends with friends for diversion. Others cut back
on their drug consumption by carrying less money with
them, or by deleting their dating apps to avoid spontan-
eous blind dates. One explained:
With the life I lead, it [the risk] can only be minim-
ally reduced. And I’d rather have, for example, one
encounter less and with that have the risk only once
instead of twice. Rather that than … use a rubber
and then not have any fun anymore. (P6, 42 yrs)
Men in this group were also tremendously impressed by
the effectiveness of the new medical treatment options.
However, if the behavioral changes were insufficient to
prevent reinfection, they could definitely imagine an-
other round of medical treatment as an option. Aware
that they were only partially changing their risk beha-
vior—and that this might not be enough—they changed
what they believed was feasible to achieve success. One
participant explained:
What I want or should do, I am absolutely still
aware. I knew it before, but the program has created
more awareness. But I am not so good at implemen-
tation, or actually not good at all so to speak. But I
do think, I do some of the things, but just not all
that I have wanted to do. (P10, 44 yrs)
For this group, risk reduction contributed importantly to
living as long as possible without hepatitis C. Having
chosen to minimize risks (to the best of their perceived
ability) they knew this strategy left them vulnerable to
reinfection. Compared with the first group, they made
few compromises, but hoped to live as long as possible
without hepatitis C.
Accept risks: live with the risk of hepatitis C
The third sense-making group included men who were
highly concerned with hepatitis C more for fear of sexual
rejection than health problems. They described the
intervention as useful to help them reconsider their own
sexual risk behavior and to realize that further behavior
changes would require considerable effort to avoid re-
infection—in contrast to medical treatment, which they
perceived as “easy.” In this sense, they expected to either
undergo repeated rounds of treatment or, if necessary,
stay HCV re-infected.
As in the second group, men with this sense-making
style had only known of their hepatitis C infection for a
relatively short time (median 1.5 years); however, as in the
first group, the diagnosis had elicited an intervention-
independent, active and intensive search for information
to explain and understand the infection. Two stated, for
example, that they had already undergone at least one suc-
cessful Interferon-based therapy and that they had then
sought information to allow them to consciously protect
themselves against reinfection. Based on the extent of
their knowledge at that time and how they viewed the first
(successfully treated) infection, they had decided on cer-
tain behavioral changes, such as “avoiding fisting.”
Two men living together as partners reported other
experiences. As both had HIV/HCV co-infection, they
saw no need to change their behavior. They described
their joint status even as a relief. They could set the
topic of hepatitis C aside:
What was easy for us was that we had the same
thing. He was positive [HIV and HCV] and me, too.
That’s why we got together, because we supported
each other. Because how do you want to find a life
partner that doesn’t have it, that doesn’t understand
the problems? We complemented each other well.
We each respected each other, supported, showed
affection to one another. It was probably just as
hard for him to find a life partner as it was for
me—someone that accepts and takes you as you
are. (P15, 34 yrs)
Among members of this group, attitudes toward the be-
havioral intervention reflected their intense personal
search for hepatitis-C-related information prior to the
study. Similar to the first group, they had low expecta-
tions of the behavioral intervention and mainly partici-
pated to please their physicians, who they believed truly
worried about them. However, having already gained
considerable knowledge and practiced changing some of
their behavior, they did not see themselves as the right
people for an intervention. Unlike the first group, but
analogous to the second, they had not tried to com-
pletely eliminate the risk of reinfection but had selected
easy risk-reduction adaptations. Still, two members of
this group who contracted HCV again despite such
changes were dumbfounded. As one said:
When you can’t pin it [the infection] down—you
know, I mean—the first time it was so nice, because
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I knew exactly where it [hepatitis C] came from,
where I got it, from whom. I knew out of which
situation it came. Then it’s easy to say, ‘Ok, I’ll
change something.’ But when later I stand there and
the liver values are high and I can’t link it to any
specific situation, then it’s difficult to change any-
thing. (P14, 46 yrs)
These men did not participate in the intervention pri-
marily to learn and expand their knowledge, but rather
as a place where they could openly talk about past diffi-
cult situations and about their failures. Therefore, they
talked with the counselor, for example, about the diffi-
culty of disclosing their HCV status. While they ac-
knowledged that this was an important preventive
measure, they found it difficult because of the rejection
they experienced as a result:
It’s hard to change much. Because in the moment
you don’t want to talk about it. Because that’s when
you want to party, have sex, you want to enjoy and
you don’t want to say, ‘Hey stop! Hepatitis C!’ Then
everything would be over. (P16, 54 yrs)
The men in this third group saw little possibility of pro-
tecting themselves more effectively in the future: similar
to those in the second group, they considered strict use
of condoms, monogamy or even total rejection of sexu-
alized drug use as effective protective measures, but con-
sidered such adaptations too extreme and difficult. This
was described particularly succinctly by one partici-
pant—a self-professed “sex and drug addict”—who ac-
knowledged that, while the intervention made sense, it
was not intensive enough for his needs.
This group saw only one feasible restriction: “having
fewer sexual encounters.” Unlike the second group, these
men knew how easily they could be infected with HCV,
but insisted on continuing risky “non-negotiable behav-
iors” and expected to be re-infected at any time. One
man called this approach—taking risks to enjoy sex—
“Russian roulette.” This group considered the new DAAs
a good and important option compared to the challenges
of behavioral change. One man exemplified this attitude:
That would probably also go in that direction with
hepatitis C. … It will become less expensive to treat
and then it will become even less a topic for some
people, like myself, to think about having sex with a
condom. (P5, 54 yrs)
They recognized the great benefit of successful therapy:
“the liver gets a break.” At the same time, though, the
cure appeared to elicit ambivalence. While it greatly de-
creased their potential liver-related morbidity, it also
meant “having to watch out again.” One described it
anxiously as “feeling put back to the time with HIV before
the [2008] Swiss Statement”. At that time, when condom
use was strongly promoted, he experienced his sexual
life as more limited and less pleasurable.
Thanks to the availability of curative therapy, members
of this group hoped that all MSM would regularly be
tested for HCV and receive treatment as necessary. They
were convinced that this would reduce the danger of
HCV infection for their sexual partners. Having rejected
major behavioral changes, they intended to live with the
risk of hepatitis C, i.e., they believed that their only rea-
sonable course of action was to accept the risks.
Discussion
This study adds considerably to the understanding of
how HIV/HCV co- and/or re-infected men responded to
one of the first HCV-specific sexual risk reduction inter-
ventions to be implemented in combination with DAAs
treatment. Results show the processes engaged by partic-
ipants in how they position themselves in relation to the
program, as well as their sense-making regarding the
intervention thereafter. We identified three sense-
making groups that helped to summarize the variety of
responses regarding individual sexual risk reduction ap-
praisal, decision-making, strategies to avoid re-infection
and challenges to behavioral change.
The main theme, Giving hepatitis C a place and living
without it again, covers the continuum of sense-making,
with the lasting effects from the intervention program
influenced by two specific factors: the time of hepatitis C
diagnosis and the effectiveness of the program—includ-
ing counseling and pharmaceutical treatment—regarding
the prospect of curing their HCV.
We noted that the first experience of hepatitis C diag-
nosis was usually unexpected and often a shock. Diagno-
sis led first to reflection, then to individual explanatory
patterns regarding transmission and the perceived con-
sequences of particular sexual practices. In line with pre-
vious studies [43, 44], the behavioral change resulting
from such reflection varied between participants. Across
the cited studies, including ours, some MSM reacted to
their diagnosis by taking a sexual break or reducing sex-
ual risk behavior; others showed little or no behavior
change.
The second important experience inherent in the main
pattern was the prospect of being cured of HCV. Inter-
estingly, and in contrast to other studies’ findings, the
prospect of cure also induced negative feelings in partici-
pants for various reasons. Whereas some men described
feelings of shame (in relation to their physician) if a re-
infection were to occur, others expressed ambivalence
about once more taking the responsibility to not get in-
fected with hepatitis C again. To our knowledge, this is
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the first time that negative feelings towards an HCV
cure have been noted in the perceptions of MSM. This
contrasts sharply with the results of a study during the
era of interferon-based therapy, in which all interviewed
HIV-positive MSM spoke completely positively about
their HCV-free status [45]. Understanding more will re-
quire further research on this topic and the potential
consequences to meet the care needs of MSM. In
addition, our results emphasize the strong possibility
that reinfection will lead to stigmatization, similarly de-
scribed by Richmond et al. [46]. In the clinical setting,
professional teams should reflect upon and discuss this
potential stigma with patients.
Alongside our main theme, based on the diverse re-
sults of the participants’ sense-making work, we divided
them into three broad groups: 1) Avoid risks: get rid of
hepatitis C for life; 2) Minimize risks: live as long as pos-
sible without hepatitis C; and 3) Accept risks: live with
the risk of hepatitis C (see Fig. 1).
One meaningful difference was observed in the partici-
pant’s perceived susceptibility to HCV reinfection in re-
lation to their experience with DAAs. All individuals
perceived DAAs as a low-burden treatment; however,
whereas two groups explained that they expected a
change in outcome (from serious HCV infection to
treatable), one did not. This finding might explain cer-
tain differences in the likelihood of behavior changes
[42]. For example, men who had previously perceived
HCV infection as a major health problem, and who
therefore chose the risk avoidance sense-making strat-
egy, were most committed to behavioral change. Those
with the sense-making approach either to Minimize or
to Accept risks were particularly attracted by DAAs
treatment, the ease of which they weighed against the
perceived difficulty of behavior change, leaving them
more open to re-treatment than to behavior change. In
other words, while the prospect of not having to take
HCV medications again motivated some towards chan-
ging their behavior, that was not universal. This supports
the findings of a recent study in which Lambers et al.
[45] described the impact of perceived treatment burden
on motivation towards behavior change. However, the
variety of experience, ranging from treatment instead of
behavioral change, towards treatment as an option if risk
reduction fails to treatment as the one single change to
get rid of HCV, has not been described so far and is in-
formative for prevention initiatives combining treatment
and counseling.
Another meaningful difference between these groups
was in the risk perception of participants, namely what
they experienced as their personal risks regarding re-
infection. For example, men from the Avoid risks group
seemed convinced that condomless anal intercourse or
past sexual drug use had led to their HCV infection. As
a consequence, they intended to protect themselves by
avoiding virtually any risky situations. In contrast, many
from the other two groups were convinced that it was
not condomless anal intercourse that led to their HCV
infection but other, more complex behaviors, e.g., using
drugs, sharing sex toys or fisting without gloves. There-
fore, they perceived that only changing such high-risk
behaviors would offer adequate protection.
The risk minimizers, who first recognized the risks
entailed by many behaviors during the sexual risk reduc-
tion intervention, perceived the elimination of those
practices as feasible. In contrast, as the risk accepters
had already tried such changes without success, they saw
no net value in renewing their earlier attempts. Import-
antly, this finding is consistent with Bandura’s concept
of self-efficacy [42], i.e., the principle that a person’s per-
ceived capability to perform a target behavior influences
their decisions for or against changes that depend on
that behavior. This implies that intervention programs
need to include components that strengthen self-
efficacy, according to the groups, the dosage might be
tailored.
The groups were further differentiated regarding the
timing and delivery of behavior changes after study re-
cruitment. For this intervention, we recruited only men
who reported condomless anal intercourse with non-
steady partners in the last year. Whereas the risk
avoiders had already initiated behavior change by the
start of the behavioral intervention, the other two had
not. According to the Transtheoretical model of change
(TTM) [47], which describes five stages of change (ran-
ging from precontemplation to maintaining behavior
changes), these men had already reached the “acting”
phase at the start of the counseling intervention. They
used the behavioral intervention to maintain and
stabilize the changes that they had already made.
In contrast, the risk minimizers responded to their
counseling with their first serious reflection on their risk
behavior. This led them to target and implement behav-
ioral changes as encouraged via motivational interview-
ing techniques [48]. In relation to the TTM [47], by the
end of the intervention program, these men had reached
the phase of either “preparation” or of “action.” Mem-
bers of the Accept risks group described no motivation
for a new attempt at behavioral change but reported re-
flection of their behavior during the intervention. These
men either relied completely on access to successful
therapy or resigned themselves to life with chronic HCV
infection. Accordingly, they seemed to be trapped be-
tween the TTM phases of “precontemplation” and
“contemplation.”
The diversity of responses to each step of the program
illustrates that, in research studies, as in clinical practice,
screening, diagnosis and treatment all offer teachable
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moments. That is, participants’ openness to information
and reflection can arise at any point of contact; and
when it does, it can serve as a fulcrum for motivational
support by clinicians [49, 50]. Additionally, the sense-
making attitudes of the three groups emphasize the need
for related interventions to support tailoring regarding
content, duration and timing. For example, by shorten-
ing the behavioral intervention for the Avoid risks group,
we could focus more on maintaining behavioral change;
and for those reporting sexualized drug use behavior, ex-
tending the behavioral intervention would allow a
sharper focus on overcoming their ambivalence and ini-
tiating change towards lower-risk practices.
Considering the strengths and weakness of the
methods described above, although the participant inter-
views were conducted 6 to 12months post-intervention,
the stories from the interviewees reflected rich, mean-
ingful, well-remembered experiences regarding the inter-
vention. One clear limitation was our decision to use a
purposive sampling strategy instead of interviewing all
51 participants. Whereas the used strategy worked well
to include individual characteristics (e.g., age distribu-
tion, years since HIV or HCV diagnosis), we did not
reach maximum variation between centers, as we were
unable to recruit participants from Switzerland’s French-
speaking region. Therefore, our results fail to represent
one major region. However, the diversity of responses to
the complex intervention program (behavioral counsel-
ing and DAAs therapy) should be sufficient to support
not only a subsequent mixed-methods quantitative out-
come evaluation, but also the advancement and tailoring
of an intervention program focusing on HCV micro-
elimination.
In summary, this study’s findings indicate a need for
further development regarding related interventions and
clinical practice. It is essential to bear in mind that, for
this subgroup of MSM co-infected with HIV and HCV,
both the sexual risk reduction intervention and curative
DAAs treatment influence future behavioral changes.
Conclusion
Via an inductive interpretative approach to explore
responses to a comprehensive HCV prevention initia-
tive, this study helped us both to understand the di-
versity of participant responses and their decisions
regarding sexual risk behavior. Participants responded
to all aspects of the study, including HCV screening,
diagnosis, treatment and counseling, with reflection
toward behavioral change. The variety of experiences
also impacted participants. Our results provide im-
portant insights into the wide range of responses after
receiving a combined prevention intervention includ-
ing treatment and counseling.
The results will facilitate ongoing development of this
and similar programs’ behavioral interventions, particu-
larly by identifying intervention components that can be
tailored to fit each target group’s attitudes/beliefs. Impact
can be tailored by adjusting how much of the intervention
is received and/or how long the intervention lasts. These
results also imply important recommendations for clinical
practice to enhance the effectiveness of infection preven-
tion components. Participants appreciated individual
counseling; and clinicians were well-positioned to first ini-
tiate and stimulate risk-related discussions, and then in
turn those discussions into teachable moments by ad-
dressing and planning concrete behavioral changes.
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